Management and Board of Directors

Terence S. Russell, Ph.D., President and CEO, member Board of Directors

Dr. Russell is an experienced entrepreneur and scientist.  He is currently the President and Chief Executive Officer of Makoto Life Sciences, Inc., a biotechnology company focused on the identification of novel pharmaceutical targets in oncology, urology, and allergic inflammation.  Dr. Russell is also a founder of Critical Biologics Corporation, a critical care pharmaceuticals company.  Previously, Dr. Russell was the Managing Partner of Vevionics, LLC, an engineering research and design company that developed innovative technologies for industrial process control and measurement.  He was also the founder of LifeBeam Technologies, Inc., a high-speed genomics technology company where he was the inventor of LifeBeam’s patented core DNA sequencing technology.  In addition to his entrepreneurial efforts, Dr. Russell has conducted research at Harvard University and Boston University on a wide range of topics; from detectors for biological warfare agents to genetically engineered proteins used in anti-counterfeiting applications.  Dr. Russell is also the Managing Partner of Zensei Analytics, LLC, a Boston-based new venture creation and consulting company.  He holds a Ph.D. in Physics from Boston University.

James W. Fordyce, Chairman of the Board of Directors

Mr. Fordyce is Managing Partner of MEDNA Partners LLC, a private advisory firm, located in Cambridge, Massachusetts.  The firm provides advisory services in the medical and life sciences fields. Mr. Fordyce has more than 25 years of experience as a private equity investor. He was a founding General Partner of Prince Ventures LP, where he was responsible for investments in a number of early stage private companies in the biotechnology, medical device and medical services sectors. Mr. Fordyce has served as a member of the boards of both private and public companies. He holds an MBA from the Harvard Business School and degrees from both Oxford University and the University of Pennsylvania. Mr. Fordyce is Chairman of the Board of Directors of the Albert and Mary Lasker Foundation, based in New York City. He is an Honorary Life Trustee of the American Cancer Society and has served on the boards of a number of health care related not- for-profit organizations.

Gavin MacBeath, Ph.D., member Board of Directors, member Scientific Advisory Board

Dr. MacBeath is an Associate Professor in the Department of Chemistry and Chemical Biology at Harvard University. He is also an Associate Member of the Broad Institute of Harvard and MIT. Professor MacBeath received his B.Sc. (Honors) degree in Genetics from the University of Manitoba in Winnipeg, Canada in 1991 and his Ph.D. in Macromolecular and Cellular Structure and Chemistry with Dr. Don Hilvert at The Scripps Research Institute in La Jolla, CA in 1997. He then pursued post-doctoral work as a Cancer Research Institute postdoctoral fellow in the lab of Stuart Schreiber at Harvard, where he developed small molecule microarray technology for high-throughput screening. In 2000, Dr. MacBeath was hired as the first research fellow at the Bauer Center for Genomics Research and in 2002 he was appointed Assistant Professor in the Department of Chemistry and Chemical Biology at Harvard University. He was promoted to Associate Professor in 2006. Over the past four years, Dr. MacBeath’s lab has pioneered the development of protein microarray technology and is currently using this technology to gain a more integrated understanding of how protein networks control complex biological processes. He is also interfacing protein microarray technology with high-throughput screening to extend the field of chemical genomics. Dr. MacBeath is the recipient of numerous awards, including the W.M. Keck Foundation Distinguished Young Scholars in Medical Research Award, the Arnold and Mabel Beckman Foundation Young Investigator Award, and the Smith Family New Investigator Award. He is also the recipient of the TR100 award, where he was named one of the top 100 young innovators in technology and business by MIT’s Technology Review Magazine. Professor MacBeath is a founding member of Merrimack Pharmaceuticals, Inc. where he is currently an advisor. He is also an advisor to Nephromics, LLC.